Key result
Long-term ascorbic acid treatment significantly improved flow-mediated dilation compared to placebo (9.0% vs 7.9%; P=0.005) in patients with coronary artery disease.
Why the study?
Does ascorbic acid improve EDNO-dependent flow-mediated dilation in patients with coronary artery disease?
Population
46 patients with angiographically established coronary artery disease (CAD)
Comparison
Ascorbic acid, single-dose followed by long-term… vs Matching placebo
Design
RCT, randomized, double-blind
Follow-up
30 days
Authors
Loading...
Supports ascorbic acid for endothelial function in CAD; extends acute RCT benefits to sustained long-term use.
RCT (n=46)
double-blind
randomized
Does ascorbic acid improve EDNO-dependent flow-mediated dilation in patients with coronary artery disease?
Absolute Event Rate: 9% vs 7.9%
p-value: p=0.005
Both single-dose and long-term ascorbic acid administration significantly improve endothelial vasomotor function in patients with coronary artery disease.
Gokce et al. (1999) conducted an RCT in Coronary artery disease (n=46). Ascorbic acid vs. Placebo was evaluated on EDNO-dependent flow-mediated dilation of the brachial artery (p=0.005). Long-term ascorbic acid treatment significantly improved flow-mediated dilation compared to placebo (9.0% vs 7.9%; P=0.005) in patients with coronary artery disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: